Revenue eBrief No. 205/19
Update to VAT Tax and Duty Manual
This guidance sets out the VAT treatment of human blood, human blood plasma, pharmaceutical products derived from human blood plasma and recombinant products. It also highlights the change of VAT treatment of human blood plasma and pharmaceutical products derived from human blood plasma.
The Court of Justice of the European Union’s (CJEU) judgment in Case C-412/15 TMD held that human blood plasma intended to be used in the manufacturing of pharmaceutical products is subject to VAT. This VAT treatment will take effect from 1 January 2020 (see paragraph 2.2).
Revenue previously treated pharmaceutical products derived from human blood plasma as exempt from VAT. From 1 January 2020 this practice will cease, and theseproducts will be subject to VAT (see paragraph 3).